A single centre, pilot trial of YF476 in patients with chronic atrophic gastritis, hypergastrinaemia and type I gastric carcinoids - YF476 and type I gastric carcinoids

Trio Medicines Ltd0 个研究点目标入组 10 人开始时间: 2010年6月21日最近更新: 2020年5月11日

试验速览

暂无简介。

•We include patients who meet the following criteria.
•*Patients known to have gastric carcinoids associated with chronic atrophic gastritis and hypergastrinaemia, and who attend the out-patient clinic of the investigators;
•*Men, post-menopausal women, pre-menopausal women who have been sterilised by tubal ligation, hysterectomy or bilateral oophrectomy, or pre-menopausal women using reliable contraception: condom and spermicide or intra-uterine device;
•*Adults = 18 years;
•*Good general health; and
•*Able to give fully-informed, written consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 5
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 5

•We exclude participants who meet the following criteria:
•*Women who are pregnant, lactating or using a steroid contraceptive;
•*History of gastric surgery, apart from surgery for gastric carcinoids;
•*Evidence of Zollinger-Ellison syndrome;
•*Prolonged QTc interval (>450 msec);
•*Certain medicines and herbal remedies taken during the 7 days before Visit 1 (see protocol);
•*Previous treatment with somatostatin; or
•*Participation in other clinical trials of unlicensed medicines within the previous 3 months.

发起方